GWS’ Sunshine State CBD Tea Products to Launch at the Ontario Cannabis Store

GWS Achieves Another Milestone Partnering with Hempsana Holdings

 Vancouver, British Columbia, November 16, 2022 – Global Wellness Strategies Inc. (CSE: GWS) (Frankfurt: O3X4) (OTCQB: GWSFF) (“Global” or the “Company”) announces that the Sunshine State Tea “Spa to Go” CBD infused black tea bundle will launch in Canada at the Ontario Cannabis Store (OCS).

Sunshine State Tea is focused on health and wellness consumer goods and the combination of CBD and black tea leaves help boost the body’s defenses. The proprietary nanotechnology based formulas were developed at Intercontinental Hemp Company in Washington State one of the foremost processing companies in the USA, having been in business since 2017. The “Spa to Go” SKU bundle includes 5 unique products, consisting of three bottles of CBD infused, black tea, grapefruit-eucalyptus scented bath liquids; a body oil, body wash and body cream. The bundle also features two bonus items, a CBD infused bath bomb and shower steamer with 100 mg of CBD in each. The shower steamer dissolves on the floor of the shower to create a wonderful fresh black tea, grapefruit-eucalyptus aroma as you take a shower.

In this age of novel viruses and a strong focus on wellness, adaptogenic teas infused with CBD are a welcome trend. Black tea has a high caffeine content and when topically applied may help achieve healthy skin by fighting against skin infections and blemishes, delays premature skin aging, soothes inflammation and reduces eye puffiness. The polyphenols and tannins in black tea are linked to skin cell rejuvenation. Black tea also has catechins and flavonoids that protect your skin against UV-B induced skin damage.

About Global Wellness Strategies:

Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies.

For further information visit websites:

 www.globalwellnessstrategies.com

Or Contact Meris Kott CEO 604.484.0355 or email to info@globalwellnessstrategies.com

Further information about the Company is available on www.SEDAR.com under the Company’s profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, its financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Announcement

Breaking
News

NOVEMBER 17, 2022

Global Wellness Strategies Forms Pharma Subsidiary

Focused on Clinical Trials